Shares of Geron (GERN) rose 9% in AH trading.
Results of GERN independent review of the Mayo study: Remissions (CR+PR) in 5/22 patients; CI in another 4 patients; OR rate of 40.9%.
Notable: GERN says "no patients with CR, PR, or CI have lost their response to date."
This is an important study. For more, see the full presentation.